2YFX: Structure Of L1196m Mutant Anaplastic Lymphoma Kinase In Com Crizotinib
reference: The design of potent and selective inhibitors to overcome clinical ALK mutations resistant to crizotinib., Huang Q, Johnson TW, Bailey S, Brooun A, Bunker KD, Burke BJ, Collins MR, Cook A, Cui JJ, Dack KN, Deal JG, Deng YL, Dinh DM, Engstrom LD, He M, Hoffman J, Hoffman RL, Shen H, Johnson P, Kania RS, Lam H, Lam JL, Le P, Li Q, Lingardo L, Liu W, West Lu M, McTigue MA, Palmer CL, Richardson PF, Sach NW, Smeal T, Smith GL, Stewart AE, Timofeevski SL, Tsaparikos K, Wang H, Zhu H, Zhu J, Zou HY, Edwards M, J Med Chem. 2014 Jan 16. PMID: 24432909

This OCA Structure page
uses Jmol, developed by the Jmol Development Team (documentation).